These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1139 related items for PubMed ID: 28893185

  • 1. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB, Eldholm RS, Braekhus A, Engedal K, Saltvedt I.
    BMC Geriatr; 2017 Sep 11; 17(1):210. PubMed ID: 28893185
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 11; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 4. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.
    Alzheimers Res Ther; 2019 Dec 05; 11(1):99. PubMed ID: 31805990
    [Abstract] [Full Text] [Related]

  • 5. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
    Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE.
    Neurology; 2020 Oct 27; 95(17):e2378-e2388. PubMed ID: 32788242
    [Abstract] [Full Text] [Related]

  • 6. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.
    BMC Neurol; 2015 Apr 01; 15():51. PubMed ID: 25880550
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.
    J Alzheimers Dis; 2012 Apr 01; 29(2):319-27. PubMed ID: 22233766
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
    Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F, Euro-SCD working group.
    Alzheimers Res Ther; 2019 Jan 17; 11(1):8. PubMed ID: 30654834
    [Abstract] [Full Text] [Related]

  • 16. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.
    Arch Neurol; 1998 Jul 17; 55(7):937-45. PubMed ID: 9678311
    [Abstract] [Full Text] [Related]

  • 17. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
    Bonham LW, Desikan RS, Yokoyama JS, Alzheimer’s Disease Neuroimaging Initiative.
    Acta Neuropathol Commun; 2016 Jun 29; 4(1):65. PubMed ID: 27357286
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Jun 29; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 19. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 29; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 20. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.
    Dement Geriatr Cogn Disord; 2009 Jan 29; 27(5):458-64. PubMed ID: 19420940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.